# Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis

> **NCT00318994** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 6 (—)

## Conditions studied

- Pancreatitis

## Interventions

- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT00318994
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2005-09
- **Final completion:** 2007-05
- **Target enrollment:** 6 (—)
- **Last updated:** 2017-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00318994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00318994, "Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00318994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*